| 31.62 0.73 (2.36%) | 10-09 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 45.56 | 1-year : | 53.96 |
| Resists | First : | 39.01 | Second : | 46.2 |
| Pivot price | 32.82  |
|||
| Supports | First : | 27.37 | Second : | 22.78 |
| MAs | MA(5) : | 30.03  |
MA(20) : | 34.81 |
| MA(100) : | 38.29 |
MA(250) : | 0 | |
| MACD | MACD : | -3.7 |
Signal : | -3.6 |
| %K %D | K(14,3) : | 19 |
D(3) : | 11.8 |
| RSI | RSI(14): 34.9 |
|||
| 52-week | High : | 55.41 | Low : | 23 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ COAG ] has closed above bottom band by 40.2%. Bollinger Bands are 0% narrower than normal.
| If tomorrow: | Open lower | Open higher |
| High: | 33.98 - 34.12 | 34.12 - 34.26 |
| Low: | 29.67 - 29.8 | 29.8 - 29.93 |
| Close: | 31.4 - 31.63 | 31.63 - 31.87 |
Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology firm dedicated to transforming the treatment of blood coagulation disorders. Operating in the United States and Denmark, its mission is to enhance life and resilience for patients through innovative therapies. The company's leading pipeline candidate is HMB-001, a bispecific antibody. This asset is currently undergoing Phase 1/2 clinical trials for the preventive management of Glanzmann thrombasthenia and has progressed to Phase 2 for the prophylactic treatment of Factor VII deficiency. Additionally, Hemab is advancing HMB-002, a monovalent antibody, through Phase 1/2 clinical development. This drug is designed for the subcutaneous prophylactic treatment of Von Willebrand disease. Beyond these clinical assets, the company actively pursues numerous preclinical and discovery-stage programs. Established in 2020, Hemab Therapeutics Holdings, Inc. maintains its headquarters in Cambridge, Massachusetts.
Sun, 27 Sep 2026
76,900 Shares in Hemab Therapeutics Holdings, Inc. $COAG Bought by State Street Corp - MarketBeat
Fri, 25 Sep 2026
Director Walbert Keli's option carries a $35.72 exercise price at Hemab Therapeutics (COAG). - Stock Titan
Wed, 15 Jul 2026
Hemab Therapeutics: A Cash-Rich Coagulation Franchise With Multiple Clinical Catalysts - Seeking Alpha
Mon, 04 May 2026
Hemab Therapeutics Holdings, Inc. Common Stock (COAG) Stock Price: Oct 7 Close $28.70 - Gotrade
Mon, 04 May 2026
Hemab Therapeutics closes upsized IPO raising $346.7 million - Investing.com
Fri, 01 May 2026
Hemab Therapeutics Holdings (Nasdaq:COAG) - Stock Analysis - Simply Wall Street
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 47 (M) |
| Shares Float | 20 (M) |
| Held by Insiders | 10.7 (%) |
| Held by Institutions | 92.1 (%) |
| Shares Short | 2,040 (K) |
| Shares Short P.Month | 1,660 (K) |
| EPS | -1.78 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 9.72 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.87 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -77 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -17.77 |
| PEG Ratio | 0 |
| Price to Book value | 3.24 |
| Price to Sales | 0 |
| Price to Cash Flow | -19.1 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|